

Karyopharm Therapeutics Inc.
Form 10-Q/A
November 14, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 001-36167

Karyopharm Therapeutics Inc.

Edgar Filing: Karyopharm Therapeutics Inc. - Form 10-Q/A

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

26-3931704
(I.R.S. Employer
Identification Number)

85 Wells Avenue, 2nd Floor

Newton, MA
(Address of principal executive offices)

02459
(Zip Code)

(617) 658-0600

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 4, 2014 there were 32,700,563 shares of Common Stock, \$0.0001 par value per share, outstanding.

Explanatory Note

The purpose of this Amendment No. 1 to Karyopharm Therapeutics Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014 (the **Form 10-Q**), is solely to add references to Exhibit Nos. 10.1, 10.2 and 10.3 that were inadvertently omitted from the Form 10-Q. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, new certifications of our principal executive officer and principal financial officer are being filed as exhibits to this Form 10-Q/A.

No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Form 10-Q.

EXHIBIT INDEX

Exhibit Number	Description of Exhibit	Form	Incorporated by Reference		Exhibit Number	Filed Herewith
			File Number	Data of Filing		
10.1	Offer Letter, dated July 7, 2014, between Karyopharm Therapeutics Inc. and Mr. Justin Renz.	8-K	001-36167	August 8, 2014	10.1	
10.2	Consulting Agreement, dated August 7, 2014, between Karyopharm Therapeutics Inc. and Mr. Paul Brannelly.	8-K	001-36167	August 8, 2014	10.2	
10.3	Separation Agreement, dated August 7, 2014, between Karyopharm Therapeutics Inc. and Mr. Paul Brannelly.	8-K	001-36167	August 8, 2014	10.3	
31.1	Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.					X
31.2	Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.					X
32.1	Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	10-Q	001-36167	November 10, 2014	32.1	
32.2	Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	10-Q	001-36167	November 10, 2014	32.2	
101.INS	Instance Document					
101.SCH	Scheme Document					
101.CAL	Calculation Linkbase Document					
101.DEF	Definition Linkbase Document					
101.LAB	Labels Linkbase Document					
101.PRE	Presentation Linkbase Document					

XBRL information previously furnished on Karyopharm Therapeutics Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission on November 10, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KARYOPHARM THERAPEUTICS INC.

Date: November 14, 2014

By: */s/ Michael Kauffman, M.D., Ph.D.*
Michael Kauffman, M.D., Ph.D.
Chief Executive Officer
(Principal executive officer)

Date: November 14, 2014

By: */s/ Justin A. Renz*
Justin A. Renz
Executive Vice President and Chief Financial Officer
(Principal financial and accounting officer)